1. Rosen, JM, Jordan, CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324(5935):1670–3. doi:10.1126/science.1171837.
Google Scholar | Crossref2. Molenaar, RJ, Radivoyevitch, T, Maciejewski, JP, van Noorden, CJ, Bleeker, FE. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta. 2014 Dec;1846(2):326–41. doi:10.1016/j.bbcan.2014.05.004.
Google Scholar | Crossref3. Atai, NA, Renkema-Mills, NA, Bosman, J, Schmidt, N, Rijkeboer, D, Tigchelaar, W, Bosch, KS, Troost, D, Jonker, A, Bleeker, FE, Miletic, H, Bjerkvig, R, De Witt Hamer, PC, Van Noorden, CJ. Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. J Histochem Cytochem. 2011 May;59(5):489–503. doi:10.1369/0022155411400606.
Google Scholar | SAGE Journals4. Bleeker, FE, Atai, NA, Lamba, S, Jonker, A, Rijkeboer, D, Bosch, KS, Tigchelaar, W, Troost, D, Vandertop, WP, Bardelli, A, Van Noorden, CJ. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010 Apr;119(4):487–94. doi:10.1007/s00401-010-0645-6.
Google Scholar | Crossref5. Dang, L, White, DW, Gross, S, Bennett, BD, Bittinger, MA, Driggers, EM, Fantin, VR, Jang, HG, Jin, S, Keenan, MC, Marks, KM, Prins, RM, Ward, PS, Yen, KE, Liau, LM, Rabinowitz, JD, Cantley, LC, Thompson, CB, Vander Heiden, MG, Su, SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009 Dec 10;462(7274):739–44. doi:10.1038/nature08617.
Google Scholar | Crossref6. Xu, W, Yang, H, Liu, Y, Yang, Y, Wang, P, Kim, SH, Ito, S, Yang, C, Wang, P, Xiao, MT, Liu, LX, Jiang, WQ, Liu, J, Zhang, JY, Wang, B, Frye, S, Zhang, Y, Xu, YH, Lei, QY, Guan, KL, Zhao, SM, Xiong, Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011 Jan 18;19(1):17–30. doi:10.1016/j.ccr.2010.12.014.
Google Scholar | Crossref7. Koivunen, P, Lee, S, Duncan, CG, Lopez, G, Lu, G, Ramkissoon, S, Losman, JA, Joensuu, P, Bergmann, U, Gross, S, Travins, J, Weiss, S, Looper, R, Ligon, KL, Verhaak, RG, Yan, H, Kaelin, WG Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Feb 15;483(7390):484–8. doi:10.1038/nature10898.
Google Scholar | Crossref8. Chowdhury, R, Yeoh, KK, Tian, YM, Hillringhaus, L, Bagg, EA, Rose, NR, Leung, IK, Li, XS, Woon, EC, Yang, M, McDonough, MA, King, ON, Clifton, IJ, Klose, RJ, Claridge, TD, Ratcliffe, PJ, Schofield, CJ, Kawamura, A. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011 May;12(5):463–9. doi:10.1038/embor.2011.43.
Google Scholar | Crossref9. Losman, JA, Koivunen, P, Kaelin, WG 2-Oxoglutarate-dependent dioxygenases in cancer. Nat Rev Cancer. 2020 Dec;20(12):710–26. doi:10.1038/s41568-020-00303-3.
Google Scholar | Crossref10. Yan, H, Parsons, DW, Jin, G, McLendon, R, Rasheed, BA, Yuan, W, Kos, I, Batinic-Haberle, I, Jones, S, Riggins, GJ, Friedman, H, Friedman, A, Reardon, D, Herndon, J, Kinzler, KW, Velculescu, VE, Vogelstein, B, Bigner, DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765–73. doi:10.1056/NEJMoa0808710.
Google Scholar | Crossref11. Pirozzi, CJ, Yan, H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021 Jun 15;18:645–61. doi:10.1038/s41571-021-00521-0.
Google Scholar | Crossref12. Parsons, DW, Jones, S, Zhang, X, Lin, JC, Leary, RJ, Angenendt, P, Mankoo, P, Carter, H, Siu, IM, Gallia, GL, Olivi, A, McLendon, R, Rasheed, BA, Keir, S, Nikolskaya, T, Nikolsky, Y, Busam, DA, Tekleab, H, Diaz, LA, Hartigan, J, Smith, DR, Strausberg, RL, Marie, SK, Shinjo, SM, Yan, H, Riggins, GJ, Bigner, DD, Karchin, R, Papadopoulos, N, Parmigiani, G, Vogelstein, B, Velculescu, VE, Kinzler, KW. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26;321(5897):1807–12. doi:10.1126/science.1164382.
Google Scholar | Crossref13. Molenaar, RJ, Verbaan, D, Lamba, S, Zanon, C, Jeuken, JW, Boots-Sprenger, SH, Wesseling, P, Hulsebos, TJ, Troost, D, van Tilborg, AA, Leenstra, S, Vandertop, WP, Bardelli, A, van Noorden, CJ, Bleeker, FE. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 2014 Sep;16(9):1263–73. doi:10.1093/neuonc/nou005.
Google Scholar | Crossref14. Pansuriya, TC, van Eijk, R, d’Adamo, P, van Ruler, MA, Kuijjer, ML, Oosting, J, Cleton-Jansen, AM, van Oosterwijk, JG, Verbeke, SL, Meijer, D, van Wezel, T, Nord, KH, Sangiorgi, L, Toker, B, Liegl-Atzwanger, B, San-Julian, M, Sciot, R, Limaye, N, Kindblom, LG, Daugaard, S, Godfraind, C, Boon, LM, Vikkula, M, Kurek, KC, Szuhai, K, French, PJ, Bovee, JV. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome Nat Genet. 2011 Nov 06;43(12):1256–61. doi:10.1038/ng.1004.
Google Scholar | Crossref15. Borger, DR, Tanabe, KK, Fan, KC, Lopez, HU, Fantin, VR, Straley, KS, Schenkein, DP, Hezel, AF, Ancukiewicz, M, Liebman, HM, Kwak, EL, Clark, JW, Ryan, DP, Deshpande, V, Dias-Santagata, D, Ellisen, LW, Zhu, AX, Iafrate, AJ. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–9. doi:10.1634/theoncologist.2011-0386.
Google Scholar | Crossref16. Figueroa, ME, Abdel-Wahab, O, Lu, C, Ward, PS, Patel, J, Shih, A, Li, Y, Bhagwat, N, Vasanthakumar, A, Fernandez, HF, Tallman, MS, Sun, Z, Wolniak, K, Peeters, JK, Liu, W, Choe, SE, Fantin, VR, Paietta, E, Lowenberg, B, Licht, JD, Godley, LA, Delwel, R, Valk, PJ, Thompson, CB, Levine, RL, Melnick, A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14;18(6):553–67. doi:10.1016/j.ccr.2010.11.015.
Google Scholar | Crossref17. Mardis, ER, Ding, L, Dooling, DJ, Larson, DE, McLellan, MD, Chen, K, Koboldt, DC, Fulton, RS, Delehaunty, KD, McGrath, SD, Fulton, LA, Locke, DP, Magrini, VJ, Abbott, RM, Vickery, TL, Reed, JS, Robinson, JS, Wylie, T, Smith, SM, Carmichael, L, Eldred, JM, Harris, CC, Walker, J, Peck, JB, Du, F, Dukes, AF, Sanderson, GE, Brummett, AM, Clark, E, McMichael, JF, Meyer, RJ, Schindler, JK, Pohl, CS, Wallis, JW, Shi, X, Lin, L, Schmidt, H, Tang, Y, Haipek, C, Wiechert, ME, Ivy, JV, Kalicki, J, Elliott, G, Ries, RE, Payton, JE, Westervelt, P, Tomasson, MH, Watson, MA, Baty, J, Heath, S, Shannon, WD, Nagarajan, R, Link, DC, Walter, MJ, Graubert, TA, DiPersio, JF, Wilson, RK, Ley, TJ. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009 Sep 10;361(11):1058–66. doi:10.1056/NEJMoa0903840.
Google Scholar | Crossref18. Molenaar, RJ, Thota, S, Nagata, Y, Patel, B, Clemente, M, Przychodzen, B, Hirsh, C, Viny, AD, Hosano, N, Bleeker, FE, Meggendorfer, M, Alpermann, T, Shiraishi, Y, Chiba, K, Tanaka, H, van Noorden, CJ, Radivoyevitch, T, Carraway, HE, Makishima, H, Miyano, S, Sekeres, MA, Ogawa, S, Haferlach, T, Maciejewski, JP. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015 Nov;29(11):2134–42. doi:10.1038/leu.2015.91.
Google Scholar | Crossref19. Schumacher, T, Bunse, L, Pusch, S, Sahm, F, Wiestler, B, Quandt, J, Menn, O, Osswald, M, Oezen, I, Ott, M, Keil, M, Balss, J, Rauschenbach, K, Grabowska, AK, Vogler, I, Diekmann, J, Trautwein, N, Eichmuller, SB, Okun, J, Stevanovic, S, Riemer, AB, Sahin, U, Friese, MA, Beckhove, P, von Deimling, A, Wick, W, Platten, M. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014 Aug 21;512(7514):324–7. doi:10.1038/nature13387.
Google Scholar | Crossref20. Farshidfar, F, Zheng, S, Gingras, MC, Newton, Y, Shih, J, Robertson, AG, Hinoue, T, Hoadley, KA, Gibb, EA, Roszik, J, Covington, KR, Wu, CC, Shinbrot, E, Stransky, N, Hegde, A, Yang, JD, Reznik, E, Sadeghi, S, Pedamallu, CS, Ojesina, AI, Hess, JM, Auman, JT, Rhie, SK, Bowlby, R, Borad, MJ, Cancer Genome Atlas, N, Zhu, AX, Stuart, JM, Sander, C, Akbani, R, Cherniack, AD, Deshpande, V, Mounajjed, T, Foo, WC, Torbenson, MS, Kleiner, DE, Laird, PW, Wheeler, DA, McRee, AJ, Bathe, OF, Andersen, JB, Bardeesy, N, Roberts, LR, Kwong, LN. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017 Mar 14;18(11):2780–94. doi:10.1016/j.celrep.2017.02.033.
Google Scholar | Crossref21. Papaemmanuil, E, Gerstung, M, Bullinger, L, Gaidzik, VI, Paschka, P, Roberts, ND, Potter, NE, Heuser, M, Thol, F, Bolli, N, Gundem, G, Van Loo, P, Martincorena, I, Ganly, P, Mudie, L, McLaren, S, O’Meara, S, Raine, K, Jones, DR, Teague, JW, Butler, AP, Greaves, MF, Ganser, A, Dohner, K, Schlenk, RF, Dohner, H, Campbell, PJ. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016 Jun 9;374(23):2209–21. doi:10.1056/NEJMoa1516192.
Google Scholar | Crossref22. Venteicher, AS, Tirosh, I, Hebert, C, Yizhak, K, Neftel, C, Filbin, MG, Hovestadt, V, Escalante, LE, Shaw, ML, Rodman, C, Gillespie, SM, Dionne, D, Luo, CC, Ravichandran, H, Mylvaganam, R, Mount, C, Onozato, ML, Nahed, BV, Wakimoto, H, Curry, WT, Iafrate, AJ, Rivera, MN, Frosch, MP, Golub, TR, Brastianos, PK, Getz, G, Patel, AP, Monje, M, Cahill, DP, Rozenblatt-Rosen, O, Louis, DN, Bernstein, BE, Regev, A, Suva, ML. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 Mar 31;355(6332):eaai8478. doi:10.1126/science.aai8478.
Google Scholar | Crossref | Medline23. Popovici-Muller, J, Saunders, JO, Salituro, FG, Travins, JM, Yan, S, Zhao, F, Gross, S, Dang, L, Yen, KE, Yang, H, Straley, KS, Jin, S, Kunii, K, Fantin, VR, Zhang, S, Pan, Q, Shi, D, Biller, SA, Su, SM. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett. 2012 Oct 11;3(10):850–5. doi:10.1021/ml300225h.
Google Scholar | Crossref24. Rohle, D, Popovici-Muller, J, Palaskas, N, Turcan, S, Grommes, C, Campos, C, Tsoi, J, Clark, O, Oldrini, B, Komisopoulou, E, Kunii, K, Pedraza, A, Schalm, S, Silverman, L, Miller, A, Wang, F, Yang, H, Chen, Y, Kernytsky, A, Rosenblum, MK, Liu, W, Biller, SA, Su, SM, Brennan, CW, Chan, TA, Graeber, TG, Yen, KE, Mellinghoff, IK. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013 May 3;340(6132):626–30. doi:10.1126/science.1236062.
Google Scholar | Crossref25. Wang, F, Travins, J, DeLaBarre, B, Penard-Lacronique, V, Schalm, S, Hansen, E, Straley, K, Kernytsky, A, Liu, W, Gliser, C, Yang, H, Gross, S, Artin, E, Saada, V, Mylonas, E, Quivoron, C, Popovici-Muller, J, Saunders, JO, Salituro, FG, Yan, S, Murray, S, Wei, W, Gao, Y, Dang, L, Dorsch, M, Agresta, S, Schenkein, DP, Biller, SA, Su, SM, de Botton, S, Yen, KE. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013 May 3;340(6132):622–6. doi:10.1126/science.1234769.
Google Scholar | Crossref26. Abou-Alfa, GK, Macarulla, T, Javle, MM, Kelley, RK, Lubner, SJ, Adeva, J, Cleary, JM, Catenacci, DV, Borad, MJ, Bridgewater, J, Harris, WP, Murphy, AG, Oh, DY, Whisenant, J, Lowery, MA, Goyal, L, Shroff, RT, El-Khoueiry, AB, Fan, B, Wu, B, Chamberlain, CX, Jiang, L, Gliser, C, Pandya, SS, Valle, JW, Zhu, AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Jun;21(6):796–807. doi:10.1016/S1470-2045(20)30157-1.
Google Scholar | Crossref | Medline27. Zhu, AX, Macarulla, T, Javle, MM, Kelley, RK, Lubner, SJ, Adeva, J, Cleary, JM, Catenacci, DVT, Borad, MJ, Bridgewater, JA, Harris, WP, Murphy, AG, Oh, DY, Whisenant, JR, Lowery, MA, Goyal, L, Shroff, RT, El-Khoueiry, AB, Chamberlain, CX, Aguado-Fraile, E, Choe, S, Wu, B, Liu, H, Gliser, C, Pandya, SS, Valle, JW, Abou-Alfa, GK. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021 Sep 23. doi:10.1001/jamaoncol.2021.3836.
Google Scholar | Crossref28. Roboz, GJ, DiNardo, CD, Stein, EM, de Botton, S, Mims, AS, Prince, GT, Altman, JK, Arellano, ML, Donnellan, W, Erba, HP, Mannis, GN, Pollyea, DA, Stein, AS, Uy, GL, Watts, JM, Fathi, AT, Kantarjian, HM, Tallman, MS, Choe, S, Dai, D, Fan, B, Wang, H, Zhang, V, Yen, KE, Kapsalis, SM, Hickman, D, Liu, H, Agresta, SV, Wu, B, Attar, EC, Stone, RM. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Feb 13;135(7):463–71. doi:10.1182/blood.2019002140.
Google Scholar | Crossref29. DiNardo, CD, Stein, EM, de Botton, S, Roboz, GJ, Altman, JK, Mims, AS, Swords, R, Collins, RH, Mannis, GN, Pollyea, DA, Donnellan, W, Fathi, AT, Pigneux, A, Erba, HP, Prince, GT, Stein, AS, Uy, GL, Foran, JM, Traer, E, Stuart, RK, Arellano, ML, Slack, JL, Sekeres, MA, Willekens, C, Choe, S, Wang, H, Zhang, V, Yen, KE, Kapsalis, SM, Yang, H, Dai, D, Fan, B, Goldwasser, M, Liu, H, Agresta, S, Wu, B, Attar, EC, Tallman, MS, Stone, RM, Kantarjian, HM. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386–98. doi:10.1056/NEJMoa1716984.
Google Scholar | Crossref30. Stein, EM, DiNardo, CD, Fathi, AT, Pollyea, DA, Stone, RM, Altman, JK, Roboz, GJ, Patel, MR, Collins, R, Flinn, IW, Sekeres, MA, Stein, AS, Kantarjian, HM, Levine, RL, Vyas, P, MacBeth, KJ, Tosolini, A, VanOostendorp, J, Xu, Q, Gupta, I, Lila, T, Risueno, A, Yen, KE, Wu, B, Attar, EC, Tallman, MS, de Botton, S. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 Feb 14;133(7):676–87. doi:10.1182/blood-2018-08-869008.
Google Scholar | Crossref31. Stein, EM, DiNardo, CD, Pollyea, DA, Fathi, AT, Roboz, GJ, Altman, JK, Stone, RM, DeAngelo, DJ, Levine, RL, Flinn, IW, Kantarjian, HM, Collins, R, Patel, MR, Frankel, AE, Stein, A, Sekeres, MA, Swords, RT, Medeiros, BC, Willekens, C, Vyas, P, Tosolini, A, Xu, Q, Knight, RD, Yen, KE, Agresta, S, de Botton, S, Tallman, MS. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722–31. doi:10.1182/blood-2017-04-779405.
Google Scholar | Crossref32. Mellinghoff, IK, Penas-Prado, M, Peters, KB, Burris, HA, Maher, EA, Janku, F, Cote, GM, de la Fuente, MI, Clarke, JL, Ellingson, BM, Chun, S, Young, RJ, Liu, H, Choe, S, Lu, M, Le, K, Hassan, I, Steelman, L, Pandya, SS, Cloughesy, TF, Wen, PY. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin Cancer Res. 2021 Aug 15;27(16):4491–9. doi:10.1158/1078-0432.CCR-21-0611.
Google Scholar | Crossref33. Heuser, M, Palmisiano, N, Mantzaris, I, Mims, A, DiNardo, C, Silverman, LR, Wang, ES, Fiedler, W, Baldus, C, Schwind, S, Pardee, T, Perl, AE, Cai, C, Kaulfuss, S, Lagkadinou, E, Rentzsch, C, Wagner, M, Wilkinson, G, Wu, B, Jeffers, M, Genvresse, I, Kramer, A. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia. 2020 Nov;34(11):2903–13. doi:10.1038/s41375-020-0996-5.
Google Scholar | Crossref34. Mellinghoff, IK, Ellingson, BM, Touat, M, Maher, E, De La Fuente, MI, Holdhoff, M, Cote, GM, Burris, H, Janku, F, Young, RJ, Huang, R, Jiang, L, Choe, S, Fan, B, Yen, K, Lu, M, Bowden, C, Steelman, L, Pandya, SS, Cloughesy, TF, Wen, PY. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020 Oct 10;38(29):3398–406. doi:10.1200/JCO.19.03327.
Google Scholar | Crossref35. Tap, WD, Villalobos, VM, Cote, GM, Burris, H, Janku, F, Mir, O, Beeram, M, Wagner, AJ, Jiang, L, Wu, B, Choe, S, Yen, K, Gliser, C, Fan, B, Agresta, S, Pandya, SS, Trent, JC. Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma. J Clin Oncol. 2020 May 20;38(15):1693–701. doi:10.1200/JCO.19.02492.
Google Scholar | Crossref36. Stein, EM, Fathi, AT, DiNardo, CD, Pollyea, DA, Roboz, GJ, Collins, R, Sekeres, MA, Stone, RM, Attar, EC, Frattini, MG, Tosolini, A, Xu, Q, See,